Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD137L-DC-EBV-VAX
- Development stage
- Phase 1
- Lead developer
- National University of Singapore
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
CD137L-DC-EBV-VAX is an investigational autologous dendritic cell (DC) vaccine designed for immunotherapy of Epstein-Barr virus (EBV)-associated cancers, particularly nasopharyngeal carcinoma (NPC). The therapy uses monocyte-derived dendritic cells differentiated via reverse signaling through the CD137 ligand (CD137L), which enhances their potency in stimulating T-cell responses. These DCs are then pulsed with EBV antigens to specifically target and induce cytotoxic T lymphocyte responses against EBV-positive tumor cells. In phase I clinical trials, the vaccine demonstrated a favorable safety profile and induced anti-tumor immune responses, including partial tumor regression and prolonged progression-free survival in some patients with locally recurrent or metastatic NPC[1][3][5][9].
- Other names
- CD137L/Epstein-Barr virus-targeting autologous dendritic cell vaccineCD137L-DC pulsed with EBV antigensCD-137L-DC pulsed with EBV antigensCD 137L-DC pulsed with EBV antigens
02
Targets
TNFRSF9 (CD137 extracellular domain)EBV-TCR (Epstein-Barr virus-specific T-cell receptor)
Beyond the preview
Go deeper on CD137L-DC-EBV-VAX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD137L-DC-EBV-VAX.